TABLE 5.
Baseline | 5 min | 10 min | 15 min | 30 min | 45 min | 60 min | 120 min | 180 min | 240 min |
---|---|---|---|---|---|---|---|---|---|
Visit one (10-mg intranasal ketamine) | |||||||||
7.5 (6–8) | 6 (5–8) | 6 (5–8) | 5 (4–7) | 4.5 (2–7) | 5 (3–7) | 4.5 (3–6) | 4.5 (3–7) | 5 (3–6) | 5 (3–7) |
Change from baseline | 0.5 (0–2) p = 0.063 | 0.5 (0–3) p = 0.062 | 1 (1–2) p = 0.004 | 1 (1–5) p = 0.004 | 1 (1–4) p = 0.008 | 1.5 (1–4) p = 0.002 | 1.5 (0–3) p = 0.016 | 2 (0–3) p = 0.016 | 1.5 (1–2) p = 0.008 |
Visit two (10-mg intravenous ketamine) | |||||||||
6 (5–8) | 1 (0–3) | 0 (0–3) | 1.5 (0–3) | 2.5 (0–5) | 3 (0–5) | 3.5 (1–5) | 3.5 (1–4) | 4 (1–5) | 3 (1–4) |
Change from baseline | 4 (3–7) p = 0.002 | 5.5 (3–7) p = 0.002 | 4.5 (3–6) p = 0.002 | 2.5 (1–6) p = 0.004 | 2.5 (1–5) p = 0.004 | 2 (1–4) p = 0.004 | 2 (2–4) p = 0.008 | 1.5 (1–3) p = 0.008 | 2 (2–3) p = 0.008 |
Visit three (30-mg intranasal ketamine) | |||||||||
5.5 (5–7) | 5 (4–6) | 3 (3–6) | 3.5 (3–6) | 3.5 (2–6) | 3 (2–4) | 2.5 (2–3) | 3 (2–3) | 3 (2–3) | 3 (3–4) |
Change from baseline | 0.5 (0–1) p = 0.06 | 2 (2–3) p = 0.04 | 2 (1–3) p = 0.004 | 2 (1–3) p = 0.004 | 2 (2–3) p = 0.004 | 3 (2–3) p = 0.002 | 2 (2–4) p = 0.002 | 2 (1–5) p = 0.004 | 2 (1–2) p = 0.008 |
Visit four (50-mg intranasal ketamine) | |||||||||
6 (6–8) | 5 (3–5) | 4 (2–5) | 3 (2–5) | 2 (2–5) | 2 (2–4) | 2 (1–5) | 2 (1–5) | 2.5 (1–6) | 5 (2–6) |
Change from baseline | 1 (0–2) p = 0.047 | 2 (1–3) p = 0.008 | 4 (3–4) p = 0.004 | 4 (2–4) p = 0.004 | 4 (4–4) p = 0.008 | 4 (3–5) p = 0.008 | 4 (2–5) p = 0.008 | 3 (1–5) p = 0.008 | 1 (1–4) p = 0.008 |
Notes: Data presented as median (interquartile range). Shapiro-Wilk test used to test for normality, and more than 80 percent of the time point values were found not to have normal distribution. Therefore, all p-values presented here are for the Wilcoxon signed-rank test for not normally distributed data. Data points with p-values <0.05 are bolded.